OBIO
Orchestra BioMed Holdings, Inc.
Biotechnology · Healthcare · United States
5.91
close · 2026-10-30
value
29
cheaper than peers29
quality
1
stronger fundamentals1
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 11.11× | 49 |
| cash flow yield, 3 years ago | -8.4% | 47 |
| earnings yield, 3 years ago | -18.0% | 45 |
| cash flow yield, latest year | -13.9% | 44 |
| cash flow yield, 2 years ago | -13.0% | 42 |
| cash flow yield, 1 year ago | -14.3% | 42 |
| earnings yield, latest year | -18.8% | 42 |
| earnings yield, 2 years ago | -25.0% | 40 |
| earnings yield, 1 year ago | -28.1% | 38 |
| price to book | 18.41× | 9 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 240.5% | 9 |
| revenue growth | -89.5% | 5 |
| return on equity | -397.3% | 4 |
3 of 4 measures available
Facts
| market cap | $355M |
| free cash flow | -$31.8M |
| employees | 86 |
| first trade | 2020-08-04 |
| next earnings | not reported |
| fundamentals updated | 2026-08-21 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.11 | -1.66 | -1.48 | -1.06 |
| free cash flow | -$49.5M | -$50.8M | -$46.2M | -$29.9M |
| net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M |
| revenue | $33.5M | $2.6M | $2.8M | $3.5M |
| unusual items | $254,000 | -$68,000 | -$1.5M | -$1.0M |